Dr. Agarwal’s Health Care Approves AEHL Merger at 23:2

Dr. Agarwal’s Health Care Limited has approved the proposed merger of Dr. Agarwal’s Eye Hospital Limited into the company, with AEHL shareholders set to receive 23 AHCL equity shares for every two AEHL shares held. The transaction is intended to create one listed entity containing the group’s eye-care operations.

What did the boards approve for the proposed merger?

The boards of AHCL and AEHL approved the proposed amalgamation of AEHL with AHCL on August 27, 2025. The investor presentation on the transaction stated that the combination would create a single listed entity housing the entirety of Dr. Agarwal’s operations. The disclosure was submitted to the stock exchange as an investor presentation by AHCL, described in the filing as the promoter entity.

The proposed structure brings the eye-care activities currently represented by the two companies under AHCL. The announcement does not state that the merger has been completed. It describes a board-approved proposal, and investors should distinguish the approval from the eventual implementation of the amalgamation.

AHCL is incorporated in 2010 and describes itself as India’s largest eye-care services chain by revenue from operations. The company cites CRISIL research in support of its market position. Its offerings include cataract and refractive surgeries, consultations, diagnostics, non-surgical treatments, optical products, contact lenses, accessories and eye-care pharmaceutical products.

How will AEHL shareholders be compensated in the transaction?

AEHL shareholders other than AHCL are proposed to receive 23 equity shares of AHCL for every two equity shares they hold in AEHL. According to the investor presentation, this exchange ratio implies a 15% premium to AEHL’s 10-day volume-weighted average price, or VWAP, as referenced in the presentation.

The same presentation said AEHL proposed a preferential allotment of ₹70 crore to AHCL. The stated purpose of this allotment is to finance ongoing capital expenditure requirements. No further breakdown of the intended capital expenditure, timing of spending or individual projects was provided in the supplied disclosure.

For investors, the exchange ratio and the preferential allotment are the central disclosed financial terms of the proposal. The share-swap structure determines how eligible AEHL shareholders would participate in the combined entity, while the proposed allotment is intended to provide funding for AEHL’s continuing expansion-related requirements.

What business will the combined listed entity represent?

The combined listed entity is proposed to represent the full Dr. Agarwal’s eye-care platform across India and Africa. At the time of the August 2025 merger presentation, AHCL said it served patients through 230 facilities in 14 states and five Union Territories in India, alongside 19 facilities across nine African countries.

The company said 79 Indian facilities were located in Tier-I cities and 151 were in other cities. This mix reflects its hub-and-spoke operating model, under which larger facilities can support a broader network of centres. AHCL says this model is designed to deepen geographic reach, improve patient accessibility and use critical clinical resources efficiently across its network.

The company’s materials also identify AHCL as India’s largest eye-care services chain with a 25% market share. The supplied information says AHCL had more than twice the revenue from operations of the second-largest eye-care services chain in India in FY2023. These rankings provide context for the merger because the proposal concerns two entities within a large specialist healthcare network rather than a diversification into a new service segment.

How has AHCL expanded since its February 2025 listing?

AHCL listed on February 4, 2025 and raised ₹3,027 crore, which the company described as India’s largest hospital initial public offering. The listing gave the eye-care group a publicly traded platform before the proposed internal consolidation involving AEHL.

In its August 2025 Q1 FY2026 investor presentation, AHCL reported 22.3% year-on-year growth in total income and 108.9% year-on-year growth in profit after tax. The presentation also cited 705,214 patients served, 78,882 surgeries performed, 857 doctors and 1,884 paramedics. The supplied material does not provide comparable prior-period absolute income or profit figures.

Later investor presentation excerpts describe a larger footprint. The October 2025 H1 FY2026 presentation referred to 239 facilities in India across 14 states and five Union Territories, as well as 19 facilities in nine African countries. Network figures in company presentations can vary with the reporting date, so the August merger disclosure and later operational presentation should be read as separate snapshots.

Why does the merger matter to AHCL investors and operations?

The merger matters because it proposes to place Dr. Agarwal’s operations in one listed company, while retaining AHCL as the listed vehicle. This may make the group structure more direct for shareholders, but the supplied disclosures do not provide projected cost savings, earnings effects, integration expenses or a completion timetable. Those outcomes cannot be inferred from the board approval alone.

For the operating business, the proposed combination is connected to a network that spans metropolitan and non-metropolitan Indian locations and nine African countries. AHCL’s focus on comprehensive eye care and its hub-and-spoke model means that capacity additions, doctor deployment and capital expenditure remain relevant to how the network serves patients.

No share-price movement, analyst forecast or customer impact was included in the material provided. The disclosed information instead centres on the exchange ratio, the proposed ₹70 crore capital infusion and the plan to consolidate the group’s operations. Investors will need to assess future regulatory and shareholder-related updates when they are disclosed.

Conclusion

AHCL’s proposed merger with AEHL is a group consolidation plan built around a 23:2 share exchange ratio and a proposed ₹70 crore preferential allotment for ongoing capital expenditure. It follows AHCL’s February 2025 listing and comes as the company reports a broad eye-care network across India and Africa.

The next disclosed matter to watch is progress on the proposed amalgamation, including any shareholder, regulatory or other implementation updates. Investors can also monitor whether AHCL provides further details on the use of capital expenditure funding, network additions and the financial effects of operating as a single listed entity.